Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables (2016 - 2025)

Historic Receivables for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $157.5 million.

  • Ascendis Pharma A's Receivables rose 33333.25% to $157.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.5 million, marking a year-over-year increase of 33333.25%. This contributed to the annual value of $190.1 million for FY2024, which is 22145.97% up from last year.
  • Per Ascendis Pharma A's latest filing, its Receivables stood at $157.5 million for Q3 2025, which was up 33333.25% from $125.0 million recorded in Q2 2025.
  • Ascendis Pharma A's Receivables' 5-year high stood at $187.7 million during Q4 2024, with a 5-year trough of $72374.2 in Q1 2021.
  • For the 5-year period, Ascendis Pharma A's Receivables averaged around $45.9 million, with its median value being $25.5 million (2021).
  • In the last 5 years, Ascendis Pharma A's Receivables plummeted by 8023.09% in 2021 and then surged by 890671.85% in 2022.
  • Over the past 5 years, Ascendis Pharma A's Receivables (Quarter) stood at $25.5 million in 2021, then dropped by 1.01% to $25.2 million in 2022, then surged by 134.3% to $59.1 million in 2023, then soared by 217.38% to $187.7 million in 2024, then fell by 16.09% to $157.5 million in 2025.
  • Its Receivables stands at $157.5 million for Q3 2025, versus $125.0 million for Q2 2025 and $70.1 million for Q1 2025.